Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1

Conditions

Melanoma 284Lymphoma, T-Cell, Cutaneous 108Mycosis Fungoides 83Sezary Syndrome 80Lymphoma, Non-Hodgkin 74Leukemia, Lymphocytic, Chronic, B-Cell 74Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 70Burkitt Lymphoma 68Lymphoma, Mantle-Cell 67Lymphoma, B-Cell, Marginal Zone 67Hodgkin Disease 67Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 65Lymphoma, Large-Cell, Immunoblastic 65Lymphoma, Large-Cell, Anaplastic 62Lymphoma 58Immunoblastic Lymphadenopathy 56Intraocular Lymphoma 43Breast Neoplasms 41Skin Neoplasms 40Neoplasms 37Carcinoma, Renal Cell 35Waldenstrom Macroglobulinemia 33Neoplasm Metastasis 33Uveal Melanoma 29Leukemia, Myeloid, Acute 23Leukemia, Hairy Cell 23Carcinoma, Non-Small-Cell Lung 22Sarcoma 21

Interventions

antineoplaston AS 2-1 1antineoplaston A10 1Complementary Therapies 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Growth Hormone-Secreting Pituitary Adenoma × Dermatologic × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡